Tier 2 — strong

Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers

Kyung-Hea Lee, Eunju Park, Hye-Jin Lee, Myeong-Ok Kim, Yong-Jun Cha, Jung-Mi Kim, Hyeran Lee, Min-Jeong Shin
Nutrition research and practice 2011 5(1):28-33

Bibliography

PubMed
PMID 21487493
PubMed Central
PMC3061266
DOI
10.4162/nrp.2011.5.1.28
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled parallel trial
ModelHuman intervention research
Sample92 male smokers; 49 supplemented and 43 controls
InterventionOnion-peel-derived supplement providing quercetin 100 mg/day
Duration10 weeks
EndpointsBlood pressure; Lipid measurements; Glucose and insulin measures; Inflammatory measures

What the study showed, in plain terms

Published in 2011, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled parallel trial. Sample/model: 92 male smokers; 49 supplemented and 43 controls. The exposure or intervention was Onion-peel-derived supplement providing quercetin 100 mg/day. Follow-up or treatment period: 10 weeks.

Selected lipid, glucose, and pressure measures improved, while IL-6 and soluble VCAM-1 did not.

Extract-based intervention and surrogate outcomes. Some findings emphasize within-group changes, and the study did not test cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected lipid, glucose, and pressure measures improved, while IL-6 and soluble VCAM-1 did not.
  • The recorded outcome domains were Blood pressure; Lipid measurements; Glucose and insulin measures; Inflammatory measures.
  • The result applies to the tested exposure: Onion-peel-derived supplement providing quercetin 100 mg/day; 10 weeks.

What this study can and cannot tell us

  • Extract-based intervention and surrogate outcomes. Some findings emphasize within-group changes, and the study did not test cardiovascular events.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology